Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR (mammalian target of rapamycin) signaling pathways.
The company’s development strategy is committed to transforming the treatment of cancer by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients with RAS-addicted cancers.
Revolution Medicines’s proprietary tri-complex technology platform enables a highly differentiated approach to inhibiting the active form of RAS, or RAS(ON). The biotechnology company is developing a portfolio of compounds that are the first and only RAS(ON) inhibitors to use this mechanism of action. To date it produced a vast collection of unique compounds including potent and cell-active RAS inhibitors that act against a number of RAS targets and address the vast majority of RAS-addicted cancers.
Revolution Medicines most advanced product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. In collaboration with their partner, Sanofi, Revolution Medicines is evaluating RMC-4630 in a multi-cohort Phase 1/2 clinical program for a range of tumor types featuring specific oncogenic mutations. Additionally, they are developing a portfolio of mutant-selective RAS inhibitors that could be the first potent, selective, cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON). The pipeline also includes inhibitors of other frontier oncology targets within the RAS and mTOR pathways.
The company has incurred net operating losses in each year since inception. As of March 31, 2021, Revolution Medicines had an accumulated deficit of $302.7 million. Revolution Medicines’s net losses were $37.2 million and $19.5 million for the three months ended March 31, 2021 and 2020, respectively.